Advaxis, Inc.
(NASDAQ : ADXS)

( )
ADXS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-0.93%291.401.4%$865.23m
AMGNAmgen, Inc.
0.28%221.311.3%$495.03m
CELGCelgene Corp.
0.39%110.001.3%$448.97m
GILDGilead Sciences, Inc.
-0.50%64.321.0%$384.61m
ILMNIllumina, Inc.
0.25%295.733.5%$305.32m
VRTXVertex Pharmaceuticals, Inc.
0.97%203.861.9%$290.09m
REGNRegeneron Pharmaceuticals, Inc.
1.20%348.412.6%$262.04m
EXASEXACT Sciences Corp.
-0.77%79.9124.0%$196.13m
ALXNAlexion Pharmaceuticals, Inc.
0.39%109.442.0%$190.16m
SGENSeattle Genetics, Inc.
2.16%110.646.1%$126.52m
BMRNBioMarin Pharmaceutical, Inc.
0.73%75.884.3%$110.72m
SRPTSarepta Therapeutics, Inc.
5.46%99.9514.6%$106.88m
AAgilent Technologies, Inc.
0.26%77.051.6%$100.02m
MRTXMirati Therapeutics, Inc.
1.12%104.332.3%$89.09m
NBIXNeurocrine Biosciences, Inc.
0.50%111.405.0%$84.24m

Company Profile

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.